Clinical Trials: Cystic Fibrosis

Birmingham : UAB/CHS Cystic Fibrosis Center

I Change Adherence & Raise Expectations

Birmingham : Site Ref # / Investigator 78920

Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)

Birmingham :

Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis

Birmingham :

Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation

Birmingham : Vertex Investigational Site

Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation

Anchorage : Site Ref # / Investigator 79256

Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)

Phoenix : Phoenix Children's Hospital

I Change Adherence & Raise Expectations

Little Rock : Novartis Investigative Site

Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

Los Angeles : University of Southern California

Prospective Observational Study to Evaluate Biomarkers of Aminoglycoside Nephrotoxicity in Patients With Cystic Fibrosis

Oakland : Kaiser Permanente Medical Care Program

I Change Adherence & Raise Expectations

Oakland : Vertex Investigational Site

Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation

Orange : Novartis Investigative Site

Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

Palo Alto :

Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation

Denver : Novartis Investigative Site

Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

Denver :

Pilot Study Testing the Effect of Ivacaftor on Lung Function in Subjects With Cystic Fibrosis and Residual CFTR Function

Hartford : Connecticut Children's Medical Center

I Change Adherence & Raise Expectations

Hartford :

Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation

Altamonte Springs : Central Florida Pulmonary Group

Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF

Gainesville : Site Ref # / Investigator 78928

Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)

Jacksonville : Novartis Investigative Site

Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

Jacksonville : Site Ref # / Investigator 78898

Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)

Orlando : Site Ref # / Investigator 78917

Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)

View More »

Tampa :

Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have a Non-G551D CFTR Gating Mutation

Atlanta : Novartis Investigative Site

Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

Atlanta : Emory University

Prevention of Cystic Fibrosis Diabetes

Atlanta : Children's Healthcare of Atlanta at Scottish Rite

Prevention of Cystic Fibrosis Diabetes

Atlanta :

Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have a Non-G551D CFTR Gating Mutation

Boise : Vertex Investigational Site

Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation

Chicago : Children's Memorial Hospital

I Change Adherence & Raise Expectations

Chicago :

Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have a Non-G551D CFTR Gating Mutation

Chicago :

Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation

Chicago : Vertex Investigational Site

Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation

Indianapolis : Riley Hospital for Children

I Change Adherence & Raise Expectations

Indianapolis : Site Ref # / Investigator 78903

Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)

Indianapolis : Riley Hospital for Children

Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF

Iowa City :

Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation

Kansas City : University of Kansas Medical Center

Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF

Lexington :

Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation

Portland : Maine Medical Center

I Change Adherence & Raise Expectations

Baltimore : Johns Hopkins University

Durability of Hypertonic Saline for Enhancing Mucociliary Clearance in Cystic Fibrosis

Baltimore :

Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation

Boston : Children's Hospital Boston

I Change Adherence & Raise Expectations

Boston : Boston Children's Hospital

Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF

Boston : Children's Hosptital, Boston

Structure and Function of Salivary Proteins

Boston :

Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have a Non-G551D CFTR Gating Mutation

Boston :

Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation

View More »

Boston : Vertex Investigational Site

Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation

Ann Arbor : University of Michigan Health System

I Change Adherence & Raise Expectations

Ann Arbor :

Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have a Non-G551D CFTR Gating Mutation

Detroit :

Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation

Grand Rapids :

Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation

Grand Rapids : Vertex Investigational Site

Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation

Minneapolis : University of Minnesota

A Study of Sweat Testing Using a Quantitative Patch

Minneapolis : Site Ref # / Investigator 79253

Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)

Minneapolis : University of Minnesota - Cystic Fibrosis Center

Prospective Observational Study to Evaluate Biomarkers of Aminoglycoside Nephrotoxicity in Patients With Cystic Fibrosis

Minneapolis :

Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have a Non-G551D CFTR Gating Mutation

Kansas City : Vertex Investigational Site

Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation

St. Louis : Novartis Investigative Site

Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

St. Louis :

Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have a Non-G551D CFTR Gating Mutation

Omaha : Novartis Investigative Site

Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

Omaha :

Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation

Las Vegas : Novartis Investigative Site

Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

Las Vegas : Children's Lung Specialists

Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF

Manchester : Site Ref # / Investigator 78957

Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)

Morristown : Novartis Investigative Site

Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

Albuquerque : UNM Clinical and Translational Center

Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF

Great Neck : Biomedical Research Alliance of New York

Cystic Fibrosis - Pediatric

New Hyde Park : Biomedical Research Alliance of New York

Cystic Fibrosis

View More »

Buffalo : Women and Children's Hospital of Buffalo

I Change Adherence & Raise Expectations

New Hyde Park : Vertex Investigational Site

Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation

New York :

Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation

Rochester : University of Rochester Medical Center

I Change Adherence & Raise Expectations

Syracuse : Site Ref # / Investigator 78912

Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)

Syracuse : SUNY Upstate University

Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF

Syracuse :

Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation

Valhalla :

Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation

Chapel Hill : UNC-Chapel Hill

Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability

Chapel Hill : UNC Hospitals

Phase 2 Study of Ex-vivo Perfusion and Ventilation of Lungs to Assess Transplant Suitability

Chapel Hill :

Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation

Chapel Hill : Vertex Investigational Site

Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation

Durham : Duke University Medical Center

I Change Adherence & Raise Expectations

View More »

Durham : Duke University Medical Center

Phase 2 Study of Ex-vivo Perfusion and Ventilation of Lungs to Assess Transplant Suitability

Bismarck : St. Alexius Medical Center

A study for cystic fibrosis patients who might have a condition called Fibrosing Colonopathy (FC).

Akron : Novartis Investigative Site

Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

Akron : Akron Children's Hospital

I Change Adherence & Raise Expectations

Cincinnati : UC Health - University of Cincinnati

Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF

Cincinnati : Vertex Investigational Site

Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation

Cleveland : Novartis Investigative Site

Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

View More »

Cleveland : Rainbow Babies and Children's Hospital

I Change Adherence & Raise Expectations

Columbus : Nationwide Children's Hospital

I Change Adherence & Raise Expectations

Columbus : Nationwide Children's Hospital, Ohio State University

Prevention of Cystic Fibrosis Diabetes

Columbus : Vertex Investigational Site

Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation

Columbus : Nationwide Children's Hospital

Use of Levemir® Improves Metabolic and Clinical Status in Cystic Fibrosis-related Diabetes (CFRD)

Toledo : Toledo Children's Hospital

I Change Adherence & Raise Expectations

Oklahoma City : Novartis Investigative Site

Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

Oklahoma City : Santiago Reyes, MD

Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF

Oklahoma City : Vertex Investigational Site

Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation

Hershey : Vertex Investigational Site

Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation

Philadelphia :

Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have a Non-G551D CFTR Gating Mutation

Philadelphia :

Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation

Pittsburgh :

Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have a Non-G551D CFTR Gating Mutation

Pittsburgh :

Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation

View More »

Pittsburgh : Vertex Investigational Site

Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation

Charleston : Novartis Investigative Site

Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

Charleston :

Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation

Charleston : Vertex Investigational Site

Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation

Columbia : Novartis Investigative Site

Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

Nashville :

Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation

Dallas : Novartis Investigative Site

Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

Dallas :

Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation

Fort Worth : Novartis Investigative Site

Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

Fort Worth :

Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation

Houston : Novartis Investigative Site

Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

View More »

Houston :

Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have a Non-G551D CFTR Gating Mutation

Houston :

Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation

San Antonio : Novartis Investigative Site

Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

Salt Kale City : Primary Children's Medical Center

I Change Adherence & Raise Expectations

Salt Lake City : University of Utah

A Study of Sweat Testing Using a Quantitative Patch

Salt Lake City :

Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation

Salt Lake City : Vertex Investigational Site

Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation

Colchester : Vertex Investigational Site

Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation

Richmond :

Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation

Seattle : Seattle Children's Hospital

I Change Adherence & Raise Expectations

Seattle :

Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation

Seattle : Vertex Investigational Site

Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation

Tacoma : Novartis Investigative Site

Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

Morgantown : West Virginia University

I Change Adherence & Raise Expectations

Morgantown :

Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation

Madison : American Family Children's Hospital

A Study of Sweat Testing Using a Quantitative Patch

Madison : Novartis Investigative Site

Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

Madison :

Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation

Milwaukee : Novartis Investigative Site

Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

Buenos Aires : Novartis Investigative Site

Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

Capital Federal : Novartis Investigative Site

Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

Córdoba : Novartis Investigative Site

Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

Paraná Entre Ríos : Novartis Investigative Site

Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

Clayton : Novartis Investigative Site

Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

New Lambton Heights : Novartis Investigative Site

Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

Victoria : Novartis Investigative Site

Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

Antwerp : University Hospital Antwerp - Universitair Ziekenhuis Antwerpen (UZA)

Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.

Leuven :

Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have a Non-G551D CFTR Gating Mutation

Pleven : Clinic of Paediatric Diseases at UMHAT Dr Georgi Stranski

Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.

Plovdiv : Clinic of Genetic and Paediatric Diseases at UMHAT Sveti Georgi

Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.

Ruse : Specialized Hospital for Active Treatment of Pulmological and Phtisiatric Disease

Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.

Varna : Multiprofile Clinic for Specialized Pediatric Clinic at MHAT Sveta Marina

Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.

Calgary : Novartis Investigative Site

Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years

Halifax : Vertex Investigational Site

Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation

Montreal : Novartis Investigative Site

Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

Montreal : Novartis Investigative Site

Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years

Toronto : Novartis Investigative Site

Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years

View More »

Winnipeg : Vertex Investigational Site

Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation

Bron : Centre de ressources et de compétences pour la mucovisidose, enfants

Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus®

Giens Cedex : Novartis Investigative Site

Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

Lyon : Centre de Ressource et de Compétence Mucoviscidose Pédiatrique Centre de Référence Mucoviscidose

Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus® /Pulmoaid® in Patients With Cystic Fibrosis

Lyon :

Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have a Non-G551D CFTR Gating Mutation

Montpellier : Novartis Investigative Site

Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

View More »

Montpellier :

Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have a Non-G551D CFTR Gating Mutation

Paris : Novartis Investigative Site

Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

Paris :

Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have a Non-G551D CFTR Gating Mutation

Reims : Novartis Investigative Site

Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

Roscoff : Novartis Investigative Site

Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

Berlin : Vertex Investigational Site

Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation

Bochum : Novartis Investigative Site

Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

Bochum : Vertex Investigational Site

Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation

Dresden : Novartis Investigative Site

Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years

Erlangen : Vertex Investigational Site

Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation

View More »

Essen : Novartis Investigative Site

Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

Essen : Novartis Investigative Site

Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years

Frankfurt : Novartis Investigative Site

Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

Frankfurt : Vertex Investigational Site

Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation

Frankfurt : Vertex Investigational Site

Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation

Hannover : Vertex Investigational Site

Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation

Jena : Jena University Hospital, Universitaetsklinikum Jena

Control of Steatorrhea in Patients With Cystic Fibrosis and Pancreatic Insufficiency

Jena : Vertex Investigational Site

Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation

Koeln : Vertex Investigational Site

Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation

Koeln : Vertex Investigational Site

Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation

Koln : Novartis Investigative Site

Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years

München : Klinikum der Universitat Munchen Medizinische Klinik-Innenstadt

Control of Steatorrhea in Patients With Cystic Fibrosis and Pancreatic Insufficiency

Munich : Vertex Investigational Site

Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation

Tubingen : University Children's Clinic Tubingen

Control of Steatorrhea in Patients With Cystic Fibrosis and Pancreatic Insufficiency

Patras : Novartis Investigative site

Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years

Thessaloniki : Novartis Investigative Site

Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years

Budapest : Novartis Investigative Site

Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

Debrecen : Novartis Investigative Site

Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years

Kaposvar : Novartis Investigative Site

Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years

Szeged : Novartis Investigative Site

Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years

Firenze : Novartis Investigative Site

Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

Genova : Novartis Investigative Site

Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

Messina : Novartis Investigative Site

Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

Napoli : Novartis Investigative Site

Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

Palermo : Novartis Investigative Site

Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

View More »

Roma : Novartis Investigative Site

Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

Verona : Novartis Investigative Site

Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

Kagawa : Site Reference ID/Investigator# 65530 Updated

Special Investigation (All Cases) of LipaCreon in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis

Kagoshima : Site Reference ID/Investigator# 65527 Updated

Special Investigation (All Cases) of LipaCreon in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis

Kanazawa : Site Reference ID/Investigator# 65529 Updated

Special Investigation (All Cases) of LipaCreon in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis

Nagoya : Site Reference ID/Investigator# 73813 Updated

Special Investigation (All Cases) of LipaCreon in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis

Sendai : Site Reference ID/Investigator# 65528 Updated

Special Investigation (All Cases) of LipaCreon in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis

View More »

Tokyo : Site Reference ID/Investigator# 67122 Updated

Special Investigation (All Cases) of LipaCreon in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis

Tsukuba : Site Reference ID/Investigator# 88673 Updated

Special Investigation (All Cases) of LipaCreon in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis

Mexico : Novartis Investigative Site

Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

Monterrey : Novartis Investigative Site

Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

Gdansk : Specjalistyczny Zespół Opieki Zdrowotnej nad Matką i Dzieckiem Poradnia Leczenia Mukowiscydozy

Control of Steatorrhea in Patients With Cystic Fibrosis and Pancreatic Insufficiency

Gdansk : Specjalistyczny Zespot Opieki Zdrowotnej nad Matka i Dzieckiem Poradnia Leczenia Mukowiscydozy

Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.

Karpacz : Centrum Pulmonologii i Alergologii w Karpaczu

Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.

Lodzi : Wojewodzki Szpital Specjalistyczny im Kopernika

Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.

Lublin : Dziecięcy Szpital Kliniczny im. Prof. Antoniego Gębali

Control of Steatorrhea in Patients With Cystic Fibrosis and Pancreatic Insufficiency

View More »

Lublin : ALERGOTEST s.c Specjalistyczne Centrum Medyczne

Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.

Poznan : Szpital Kliniczny im Karola Jonschera

Control of Steatorrhea in Patients With Cystic Fibrosis and Pancreatic Insufficiency

Poznan : Szpital Kliniczny im Karola Jonschera

Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.

Rabka Zdrój : NZOZ Sanatorium Cassia Villa Medica

Control of Steatorrhea in Patients With Cystic Fibrosis and Pancreatic Insufficiency

Rabka Zdrój : NZOZ Sanatorium Cassia Villa Medica

Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.

Rzeszow : NZOZ Podkarpacki Osrodek Pulmonologii i Alergologii

Control of Steatorrhea in Patients With Cystic Fibrosis and Pancreatic Insufficiency

Rzeszow : NZOZ Podkarpacki Osrodek Pulmonologii i Alergologii

Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.

Warszawa : IRMED Irena Wojciechowska

Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.

Warszawa : Centrum Zdrowia Matki, Dziecka i Mlodziezy

Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.

Doha : Hamad Medical Corporation

Blood Collection From Individuals With Lung Disease for Genetic Studies (Qatar)

Barnaul : Site Reference ID/Investigator# 80716 Updated

Evaluation of Safety and Tolerability of Creon Micro in Children Younger Than Four Years With Pancreatic Exocrine Insufficiency

Kazan : Novartis Investigative Site

Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years

Moscow : Site Reference ID/Investigator# 80693 Updated

Evaluation of Safety and Tolerability of Creon Micro in Children Younger Than Four Years With Pancreatic Exocrine Insufficiency

Moscow : Novartis Investigative Site

Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years

Novosibirsk : Site Reference ID/Investigator# 80698 Updated

Evaluation of Safety and Tolerability of Creon Micro in Children Younger Than Four Years With Pancreatic Exocrine Insufficiency

View More »

Novosibirsk : Site Reference ID/Investigator# 80713 Updated

Evaluation of Safety and Tolerability of Creon Micro in Children Younger Than Four Years With Pancreatic Exocrine Insufficiency

Orenburg : Site Reference ID/Investigator# 80715 Updated

Evaluation of Safety and Tolerability of Creon Micro in Children Younger Than Four Years With Pancreatic Exocrine Insufficiency

Voronezh : Site Reference ID/Investigator# 80697 Updated

Evaluation of Safety and Tolerability of Creon Micro in Children Younger Than Four Years With Pancreatic Exocrine Insufficiency

Voronezh : Novartis Investigative Site

Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years

Yaroslavl : Novartis Investigative Site

Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years

Barcelona : Novartis Investigative Site

Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

Sabadell : Novartis Investigative Site

Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

Valencia : Novartis Investigative Site

Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

Lausanne : Novartis Investigative Site

Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years

Zurich : Novartis Investigative Site

Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years

Belfast : Celerion

A Safety and Tolerability Study OF PUR118 In Subjects With Cystic Fibrosis

Belfast :

Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation

Cambridge : Vertex Investigational Site

Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation

Edinburgh :

Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation

Liverpool : Liverpool Heart & Chest Hospital

A Cross-over Study of OligoG in Subjects With Cystic Fibrosis. Fibrosis

View More »

Liverpool : Liverpool Heart and Chest Hospital

Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.

London : Royal Brompton Hospital, Department of Respiratory Medicine

Extension Study of Arikace™ in CF Patients With Chronic Pseudomonas Aeruginosa Infection

Sheffield : Sheffield Children's Hospital, The Academic Unit of Child Health

Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.